Danirixin is primarily investigated for its potential in treating respiratory conditions, particularly chronic obstructive pulmonary disease (COPD). It functions as a selective CXCR2 antagonist, which means it blocks the activity of the CXCR2 receptor involved in the migration of neutrophils to sites of inflammation. By inhibiting this pathway, Danirixin helps reduce neutrophil-driven inflammation in the airways, a key factor in the progression of COPD and other inflammatory lung diseases. It has been studied in clinical trials to evaluate its ability to reduce exacerbations and improve lung function in patients with COPD, especially those with a history of frequent flare-ups. Due to its targeted mechanism, Danirixin may offer benefits over broader anti-inflammatory treatments by minimizing systemic side effects. Research into its use remains focused on respiratory therapeutics, with potential applications in asthma and bronchiectasis where neutrophilic inflammation plays a role.